UK Article: Why Don’t We Just… reschedule psilocybin?

UK Article: Why Don’t We Just… reschedule psilocybin?
CANNANNEW REPORT

The psychedelic renaissance is upon us! Psychedelic medicine could provide much needed treatment options for some mental health and neurological disorders in the near future. However, our drug laws impede research and deny patients access to these highly effective medicines. Psychedelics include plant medicines such as psilocybin (the active constituent of magic mushrooms), Ayahuasca (a powerful psychedelic used by indigenous populations for thousands of years, often consumed as a tea), and those synthesised in the laboratory, including LSD and MDMA (ecstasy). Psilocybin is a naturally occurring molecule found in over 200 species of fungi. It is structurally similar to serotonin – a human neurotransmitter that regulates mood and perception. When administered in clinical settings with extensive psychological support (a treatment we call Psychedelic Assisted Psychotherapy, or “PAP”) psilocybin may be a safe and effective treatment for mental health disorders, particularly when other treatments have been ineffective. These disorders include severe depression, anxiety and depression occurring in terminal cancer patients, alcohol and nicotine dependence, and PTSD (post-traumatic stress disorder). There are a number of differences between PAP and current treatment approaches. Firstly, psychedelics are administered infrequently in controlled settings with up to only three treatments shown to produce long lasting benefits in clinical trials so far. Secondly, people report being healed. In psychiatry we manage symptoms and rarely heal people. In fact, in some cases, patients no longer meet the criteria for having a disorder following PAP. And lastly, infrequent dosing removes the burden of side-effects, while the clinical setting reduces risk. Further research is essential before PAP can become a medicine available on the NHS. Unfortunately, researching psychedelics is particularly difficult in both human and animal studies. It is extremely expensive (over £20,000 for one clinical trial), bureaucratic and incurs large time delays (up to one year). These drugs cannot…

Excerpt only …
READ MORE BELOW
Source : UK Article: Why Don’t We Just… reschedule psilocybin?

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.